Advertisement

Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat

  • H. O. Borbe
  • G. Niebch
  • B. Nickel
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

The monoamine oxidase (MAO) B activity of rat brain was inhibited by selegiline and its desmethyl-metabolite in vitro with IC50-values of 11.25 nmol/1 and 625.00 nmol/1, respectively. When measured in an ex vivo experiment following oral treatment of rats, the large difference in potency was distinctly reduced, from factor 60 in vitro to factor 3 ex vivo. Restoration experiments of MAO-B-activity after cessation of treatment revealed a nearly identical time course for both compounds. It is concluded that desmethyl-selegiline is an irreversible blocker of MAO-B, nearly equipotent to selegiline after multiple oral administration. No pharmacologically relevant inhibition of MAO-A was found with both compounds.

Keywords

Monoamine Oxidase Bovine Serum Albumine Restoration Experiment Relevant Inhibition Selective Monoamine Oxidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barbeau A, Murphy CF, Sourkes TL (1961) Excretion of dopamine in diseases of basal ganglia. Science 133:1706.PubMedCrossRefGoogle Scholar
  2. Birkmayer W, Hornijkiewicz O (1961) Der L-3,4 Dioxyphenylalanin (L-Dopa)-Effekt bei der Parkinson-Akinesie. Wien Klin Wochenschr 73:787.PubMedGoogle Scholar
  3. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with ‘Madopar’ and L-deprenyl in Parkinson’s disease. Lancet i:439–443.CrossRefGoogle Scholar
  4. Finberg JPM, Youdim MBH (1983) Selective MAO-A and MAO-B inhibitors: their mechanism of action and pharmacology. Neuropharmacology 22:441–446.PubMedCrossRefGoogle Scholar
  5. Glover V, Sandier M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265:80–81.PubMedCrossRefGoogle Scholar
  6. Knoll J (1976) Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Wolstenholme GEW, Knight J (eds) Monoamine oxidase and its inhibition. Elsevier, Amsterdam, pp 135–161.Google Scholar
  7. Maycock AL, Abeles RH, Salach JI, Singer TP (1976) The action of acetylenic inhibitors on mitochondrial monoamine oxidase: structure of the flavin site in the inhibited enzyme. In: Wolstenholme GEW, Knight J (eds) Monoamine oxidase and its inhibition. Elsevier, Amsterdam, pp 33–47.Google Scholar
  8. Mutschier E, Möhrke W (1983) Kinetics of MAO inhibitors. Mod Probl Pharmacopsychiatry 19:126–134.Google Scholar
  9. Salach JI, Detmer K, Youdim MBH (1979) The reaction of bovine and rat liver monoamine oxidase with 14C-clorgyline and 14C-deprenyl. Mol Pharmacol 16:234–241.PubMedGoogle Scholar
  10. Yoshida T, Yamada Y, Yamamoto T, Kuroiwa Y (1986) Metabolism of deprenyl a selective monoamine oxidase (MAO) B inhibitor in rat: relationship to MAO-B inhibitory potency. Xenobiotica 16(2): 129–136.PubMedCrossRefGoogle Scholar
  11. Young WF, Laws ER, Sharbrough FW, Weinshilboum RM (1986) Human monoamine oxidase. Arch Gen Psychiatry 43:604–609.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • H. O. Borbe
    • 1
  • G. Niebch
    • 1
  • B. Nickel
    • 1
  1. 1.Department of BiochemistryAsta Pharma AGFrankfurt/MainFederal Republic of Germany

Personalised recommendations